LRRK2 and Parkinson disease: In the replication cohort, which included 103 LRRK2 p.A419V PD carriers and 3,557 non-carriers, linear regression adjusted for sex showed a similarly significant reduction in disease onset by approximately two and a half years (β = −2.79 years, SE = 1.03; p = 0.007).